Allogeneic Transplantation for Solid Tumors

(1)

3

rd

_{ATST Meeting}

Allogeneic Transplantation

for Solid Tumors

Santa Maria della Scala Museum

Siena - March 28

th

_{, 2008}

Under the auspices of

www.sanraffaele.org - Section “Care” - Section “Conferences”

Associazione Italiana di Oncologia Medica

(2)

M

EETING

V

ENUE

Santa Maria della Scala Museum Piazza Duomo 2 - Siena, Italy

S

CIENTIFIC

C

OMMITTEE Marco Bregni

San Raffaele Scientific Institute e-mail: [email protected] Richard W. Childs

National Institutes of Health e-mail: [email protected] Naoto T. Ueno

M.D. Anderson Cancer Centre e-mail: [email protected]

O

RGANISING

S

ECRETARIAT San Raffaele Congress Centre Via Olgettina 58 - 20132 Milano, Italy

Phone: +39 02 2643 3700 - Fax: +39 02 2643 3754 e-mail: [email protected]

C.M.E. - C

ONTINUOUS

M

EDICAL

E

DUCATION

The Italian Ministry of Health will be requested to evaluate the meeting for C.M.E. The credits will be reserved only to Italian specialists in Haematology, Oncology and Pediatrics.

R

EGISTRATIONS

To register for the meeting, please send the enclosed form, duly filled in, to the Organising Secretariat, together with the proof of payment.

Registration fee covers participation to the scientific sessions, attendance certificate, welcome dinner and catering service during the meeting.

W

ELCOME DINNER

Welcome dinner will be held on Thursday evening, March 27th_{, at}_{Enoteca Italiana}_, the public institution founded in 1960 with the aim of promoting Italian wines, established within the premises of the sixteenth century Medici Fortress. Dinner is included in the delegates registration fee; accompanying persons should attend by paying €96,00 (VAT 20% included).

(3)

T

n association with the EBMT Solid Tumor Working Party, we are pleased to invite you to attend the 3rd_{International Allogeneic Transplantation for Solid}

Tumors (ATST) meeting in Siena, Italy on March 28th_{, 2008. This one day meeting}

will be held at the charming medieval Santa Maria della Scala Museum, formerly one of European oldest hospitals. The town of Siena is approximately a 40 minute car drive from Florence, where the 34th_{annual EBMT meeting will commence,}

following the ATST meeting, on March 30th_{, 2008.}

Over the past 10 years, investigators across the world have pursued investigational trials of reduced intensity allogeneic hematopoietic cell transplantation for a number of metastatic tumors to test whether the graft-vs-leukemia effect could be extended to tumors of epithelial origin. Case reports of solid tumors regressing months after the conditioning regimen have provided proof of concept of the existence of a graft-vs-solid tumor effect. Importantly, some patients with renal cell carcinoma and breast cancer achieved complete responses which persist more than 5 years after transplantation, suggesting this immune effect may have the potential to cure. The 3rd_{ATST meeting will update results on allogeneic transplantation for solid}

tumors, highlighting the collected experience with metastatic renal cell carcinoma, breast carcinoma, and colon cancer. Although reduced intensity regimens have proven to be feasible and associated with limited toxicities, new strategies that enhance the allogeneic anti-tumor response appear to be a promising area of research. Approximately sixteen world renowned experts in the field of tumor immuno-biology and allogeneic transplantation have been invited to speak on methods to enhance graft-vs-tumor effects utilizing tumor antigen specific T-cells, alloreactive NK cells, and post transplant tumor vaccine approaches. Bench to bedside studies investigating adoptive donor NK cells infusions to enhance graft-vs-solid tumor effects and the recent discovery of several new tumor antigens overexpressed on cancer cells identified using T-cells from responding transplant patients will be reviewed. Preclinical data evaluating transplant approaches that incorporate drugs inhibiting tumor angiogenesis and tyrosine kinases with activity against kidney cancer and breast carcinoma will be reviewed.

The final portion of the programme will be dedicated to constructing an international solid tumor transplant consortium to pursue multi-center studies investigating novel allogeneic immunotherapy protocols for solid tumors.

Meeting attendees are invited and encouraged to submit and present an overview of proposed transplant protocols for consideration of sponsorship by this consortium.

Marco Bregni Richard W. Childs Naoto T. Ueno

(4)

S

CIENTIFIC

P

ROGRAMME

8.00-8.15

Introduction to ATST-3 and Meeting Objectives N.T. Ueno

L

ECTURE

S

ESSION

1 Allogeneic Immunotherapy for Renal Cell Cancer

Chairpersons: J.A. Barrett and W. Herr

8.15-10.00

1. Combining mTOR and tyrosine kinase inhibitors with allogeneic immunotherapy for RCC - Impact on immune responses

P. Brossart

2. Identification of new RCC tumor antigens using allogeneic T-cells R.W. Childs

3. Adoptive NK infusions to boost graft-vs-RCC responses: from mouse to man A.E.L. Lundqvist

4. Update on allogeneic transplantation for RCC M. Bregni

L

ECTURE

S

ESSION

2 Allogeneic Immunotherapy for Breast Cancer

Chairpersons: D. Niederwieser and T. Teshima

10.15-12.00

1. Animal models of allogeneic transplantation for Breast Cancer. Lessons learned and new methods to augment GVT effects S. Slavin

2. VEGF inhibition to enhance graft-vs-tumor responses M.M. Dikov

3. Enhancing NK cell activity against Breast Cancer M.W. Lowdell

4. Can allogeneic transplantation cure metastatic Breast Cancer? Clinical updates and results of a new meta analysis

(5)

L

ECTURE

S

ESSION

3 Allogeneic Immunotherapy for Colon Cancer

Chairpersons: M. Aglietta and O. Ringdén

13.00-14.45

1. Modification of natural history of metastatic colon cancer with patient-targeted modern therapies

S. Siena

2. Combined liver and allogeneic stem cell transplantation for large primary liver cancer

O. Ringdén

3. Directing donor T-cells against CEA and survivin after transplantation to augment GVT

D. Sangiolo

L

ECTURE

S

ESSION

4 Graft-versus-tumor effect in pediatric solid tumors

Chairpersons: F. Fagioli and F. Porta

14.45-15.30

1. KIR-HLA receptor ligand mismatch enhances graft versus tumor effect in haploidentical stem cell transplantation in pediatric metastatic solid tumors A. Pérez Martínez

2. Haploidentical transplantation using CD3/19 depleted stem cells in children with refractory solid tumors

R. Handgretinger

L

ECTURE

S

ESSION

5 Development of a Solid Tumor Transplant Consortium to

systematically investigate novel allogeneic immunotherapy

regimens for select solid tumors in the multi-center setting

Chairpersons: M. Bregni and R.W. Childs

15.45-17.00

1. Project overview: conceptual multi-center design and funding M. Bregni and R.W. Childs

2. Funding mechanisms to support a European/American Solid Tumor Consortium P. Blaes and S. Giralt

(6)

Massimo Aglietta

Institute for Cancer Research

and Treatment

Candiolo - Torino, Italy

John A. Barrett

National Institutes of Health

Bethesda - Maryland, USA

Pascale Blaes

ESMO - European Society

for Medical Oncology

Brussels, Belgium

Marco Bregni

San Raffaele Scientific Institute

Milano, Italy

Peter Brossart

University of Bonn

Bonn, Germany

Richard W. Childs

National Institutes of Health

Bethesda - Maryland, USA

Mikhail M. Dikov

Vanderbilt University

Nashville - Tennessee, USA

Franca Fagioli

Università degli Studi di Torino

Torino, Italy

Sergio Giralt

M.D. Anderson Cancer Centre

Houston - Texas, USA

Rupert Handgretinger

University Hospital of Tübingen

Tübingen, Germany

Wolfgang Herr

University Hospital Mainz

Mainz, Germany

Mark W. Lowdell

Royal Free & University College

London, UK

Andreas E.L. Lundqvist

National Institutes of Health

Bethesda - Maryland, USA

Antonio Pérez Martínez

Hospital Niño Jesús

Madrid, Spain

Dietger Niederwieser

Universität Leipzig

Leipzig, Germany

Fulvio Porta

Ospedale dei Bambini

Brescia, Italy

Olle Ringdén

Karolinska University Hospital

Huddinge - Stockholm, Sweden

Dario Sangiolo

Institute for Cancer Research

and Treatment

Candiolo - Torino, Italy

Salvatore Siena

Ospedale Niguarda Ca’ Granda

Milano, Italy

Shimon Slavin

International Center for Cell

Therapy & Cancer immunotherapy

Tel Aviv, Israel

Takanori Teshima

Kyushu University Hospital

Fukuoka, Japan

Naoto T. Ueno

M.D. Anderson Cancer Centre

Houston - Texas, USA

(7)

H

OTEL ACCOMMODATION

Athena

Jolly

La Colonna

San Marco

Hotel

********

Hotel

********

Hotel

*******

Hotel

*******

Contact person Ms Serena Bianciardi Ms Aline Modena Ms Loriana Codogno Ms Sara Sangiorgi Ms Noemi Palla Ms Chiara Pagni

Address Via P. Mascagni 55 Piazza La Lizza Strada di Pescaia 73/75 Via Massetana 70

Phone number +39 0577 286313 +39 0577 382111 +39 0577 236303 +39 0577 271556

Fax number +39 0577 48153 +39 0577 382112 +39 0577 236634 +39 0577 271826

e-mail address [email protected] [email protected] [email protected] [email protected]

Web-site www.hotelathena.com www.jollyhotels.com www.hotellacolonnasiena.it www.sanmarcosiena.it

Double room €155,00Superior

(single use) rate €199,00Deluxe €160,00 € 80,00 € 95,00

Double room rate €180,00Superior

€250,00Deluxe €180,00 €110,00 €115,00

Notes Downtown and walking Downtown and 15’ distance from the 15’ distance from the distance from the walking distance from congress venue by congress venue by congress venue the congress venue free shuttle service free shuttle service

The above mentioned hotels have reserved an allotment of rooms for the 3rd_{ATST Meeting.}

All participants interested in making a reservation, should contact the preferred hotel directly, referring to the ATST Group, before January 25th_{, 2008}_.

Please be informed that the number of rooms reserved is limited; requests of accommodation will be granted on a “first come, first served” basis.

H

OW TO REACH

S

IENA

• By bus

From Firenze- www.sitabus.it(Regione Toscana - Line Firenze/Siena) SITA Bus Station next to Santa Maria Novella Railway Station - Bus “Siena Rapida”

• By train

Once arrived at Firenze S. Maria Novella Stationtake the bus “Siena Rapida” - www.trenitalia.it

• By plane

From Firenze “Amerigo Vespucci” Airport- www.aeroporto.firenze.it

Train to Firenze S. Maria Novella Railway Station and then bus “Siena Rapida”

From Pisa “Galileo Galilei” Airport- www.pisa-airport.com

Daily shuttle-bus by reservation - Journey time in 2h. -

www.trainspa.it/sienapisa.html

Train to Firenze S. Maria Novella Railway Station and then bus "Siena Rapida"

• By car

From Northern Italy

Motorway A1 exit Firenze Certosa - Highway Firenze-Siena - Exit Siena Nord

From Southern Italy

Motorway A1 exit Valdichiana - Highway 326 to Siena - Exit Siena Nord

(8)

On the cover:

Domenico Di Bartolo - XV Century “Care of the infirm” (detail) Santa Maria della Scala Museum